

PROGRESS TO DATE

We are poised to develop hundreds of novel compounds to target specific metabolic pathways for several cancer subtypes. Our founders have analyzed hundreds of preclinical specimens and assessed their therapeutic responses. We have several lead candidates for RCC, HCC, and MYC cancers in general. We have access to a large collection of HCC and RCC patient specimens that were collected according to established IRB protocols for clinical trials. We have done preliminary non-GLP toxicology and found no toxicity at 50x of our effective dose.

Intellectual property has been filed. It covers the pathway and composition of matter of our novel compounds.

Phase 1

Bacchus Therapeutics is seeking to raise seed funding, approximately \$5-6 million, to accomplish the following:

- Lead optimization
- Rodent ADME profiling
- Non-GLP Toxicology
- IND-enabling studies
- Expand the company's intellectual property
- Pursue business development activities and strategic partnerships

Our immediate focus will be on moving to IND: Declaration of development candidate for Phase 1.

Phase 2

The next funding cycles will include intellectual property portfolio expansion, further proprietary small molecule development, and expansion to other MYC and metabolic disorders.

MANAGEMENT AND DEVELOPMENT TEAM

- Dr. Dean Felsher, Founder/Professor at Stanford University, is an internationally regarded physician scientist who has over 20 years of experience as a Medical Oncologist. He directs his own research laboratory, where he conducts clinical and translational cancer research and is the founding Director of the Stanford Translational Research and Applied Medicine Program.
- Dr. Arvin Gouw, Founder/Instructor at Stanford University, has over 10 years of experience as a translational research scientist working in the field of cancer metabolism. Dr. Gouw identified a first-in-class target which causes regression of MYC-driven cancers.
- Dr. Steven Schow, Advisory Board Member, has over 20 years of experience in developing multiple novel small molecules in the private sector. He has had multiple executive leadership roles in large and small biotechnology companies.
- Dr. Robert Greenhouse, Advisory Board Member, brings over 20 years of medicinal chemistry experience. He has collaborated with Drs. Felsher and Gouw for the past 5 years under the Stanford SPARK entrepreneurship program.